Viral Vector Production (Research-Use) Industry Forecasted for Rapid Expansion, Reaching $3.56 Billion by 2030

The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

What Is the Current Market Size and Growth Rate of the Viral Vectors And Plasmid DNA Market?
The viral vector production (research-use) market size has grown rapidly in recent years. It will grow from $1.77 billion in 2025 to $2.04 billion in 2026 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to increasing investment in gene therapy research, expansion of academic and translational research programs, availability of advanced cell culture technologies, rising use of viral vectors in oncology studies, growth of contract research activities.

The viral vector production (research-use) market size is expected to see rapid growth in the next few years. It will grow to $3.56 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to increasing demand for next-generation gene delivery tools, rising adoption of automation in research laboratories, expansion of CRISPR and gene editing research, growing collaboration between academia and biopharma, increasing focus on reproducibility and standardization. Major trends in the forecast period include increasing adoption of scalable viral vector manufacturing platforms, rising demand for high-purity research-grade vectors, growing use of suspension cell culture systems, expansion of automated upstream and downstream processing, enhanced focus on vector characterization and quality control.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/viral-vector-production-research-use-global-market-report

What Are the Major Drivers Influencing the Viral Vector Production (Research-Use) Market?
The rising occurrence of genetic disorders is expected to propel the growth of the viral vector production (research-use) market going forward. Genetic disorders are diseases or conditions caused by abnormalities in an individual's deoxyribonucleic acid, which can be inherited from one or both parents or occur due to new genetic mutations. The rise in genetic disorders is due to increasing parental age, raising the likelihood of genetic mutations being passed to offspring. The growing prevalence of genetic disorders supports the growth of viral vector production (research-use) by driving demand for advanced gene delivery tools to study disease mechanisms and develop potential therapeutic approaches. For instance, in November 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based government public health agency, Trisomy 21 (Down syndrome) occurs in about 1 in 643 births, resulting in approximately 5,713 new cases annually, and Trisomy 18 occurs in about 1 in 3,336 births, or roughly 1,101 cases yearly. Therefore, the rising occurrence of genetic disorders is expected to propel the growth of the viral vector production (research-use) market.

What Segment Categories Define the Viral Vector Production (Research-Use) Market Structure?
The viral vector production (research-use) market covered in this report is segmented –

1) By Type: Adeno-Associated Virus (AAV), Lentivirus, Adenovirus, Retrovirus, Other Types
2) By Production: Transient Transfection, Stable Cell Line, Viral Packaging System, Other Production Methods
3) By Workflow: Upstream Processing, Downstream Processing
4) By Application: Gene Therapy, Vaccines, Oncology, Infectious Diseases, Other Applications
5) By End-Use: Pharmaceutical And Biopharmaceutical Companies, Research Institutes

Subsegments:
1) By Adeno-Associated Virus: Single-Stranded Adeno-Associated Virus, Self-Complementary Adeno-Associated Virus, Hybrid Adeno-Associated Virus
2) By Lentivirus: Human Immunodeficiency Virus-Based Lentivirus, Feline Immunodeficiency Virus-Based Lentivirus, Equine Infectious Anemia Virus-Based Lentivirus
3) By Adenovirus: Replication-Competent Adenovirus, Replication-Deficient Adenovirus, Helper-Dependent Adenovirus
4) By Retrovirus: Gamma Retrovirus, Spumavirus (Foamy Virus), Alpha Retrovirus
5) By Other Types: Herpes Simplex Virus Vectors, Baculovirus Vectors, Sendai Virus Vectors

What Are the Emerging Market Trends That Companies Should Monitor in Viral Vector Production (Research-Use) Market?
Major companies operating in the viral vector production market are focusing on developing advanced solutions, such as specialized cell culture media, to improve transfection efficiency, increase viral vector yields, and ensure consistent quality for research applications. Cell culture media are nutrient-rich solutions designed to support the growth and maintenance of cells outside their natural environment. They contain essential components like amino acids, vitamins, and growth factors optimized for specific cell types and applications. For instance, in January 2023, FUJIFILM Irvine Scientific, a US-based life sciences company, introduced BalanCD HEK293 Viral Feed, the world’s first chemically defined nutrient feed specifically optimized for HEK293 suspension cultures used in AAV viral vector manufacturing. Through this launch, the company aims to significantly boost adeno-associated virus (AAV) yields, with up to 67% improvement in viral packaging efficiency compared to basal media. The feed is designed for scalable gene therapy and biotech workflows, offering consistent performance across formats and compatibility with multiple media systems.

Which Are the Top Companies in the Viral Vector Production (Research-Use) Market?
Major companies operating in the viral vector production (research-use) market are Sanofi S.A., Thermo Fisher Scientific Inc., Merck KGaA, Becton Dickinson and Company, Lonza Group AG, Sartorius AG, Charles River Laboratories International Inc., FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Curia Inc., AGC Biologics GmbH, SK pharmteco Inc., Oxford Biomedica Plc, Waisman Biomanufacturing, Voyager Therapeutics Inc., FinVector Oy, Batavia Biosciences BV., GENEZEN LABORATORIES, BioNTech IMFS GmbH, VGXI Inc., Tonix Pharmaceuticals, Cell and Gene Therapy Catapult, Mustang Bio Inc.

Get the full viral vector production (research-use) market report here:
https://www.thebusinessresearchcompany.com/report/viral-vector-production-research-use-global-market-report

How does the Viral Vector Production (Research-Use) Market perform across different regions?
North America was the largest region in the virtual vector production (research-use) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector production (research-use) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn